← Wuhan Hiteck Biological Pharma overview

Wuhan Hiteck Biological Pharma vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Wuhan Hiteck Biological Pharma Co Ltd (300683.CS)

Q3 2026
▲2▼2

Hiteck's losses widen as chondrosarcoma drug advances

  • Losses keep widening, revenue falling Hiteck's 2026 interim report showed the net loss swelling to 78.71 million yuan, with revenue down 18% and gross margin slipping to 34.25%. A company that keeps losing more money and selling less worries investors, which weighs on the share price.

    The widening loss and falling revenue are the core financial drag on the stock.

  • Chondrosarcoma drug trial approved Regulators approved human trials of Hiteck's injectable epratuzumab for chondrosarcoma, a bone cancer with no approved drug. It is a first-in-class therapy, so success could open a new market, though trials take years and carry high risk.

    This is the main new pipeline catalyst that could lift the stock.

  • Gene therapy investee also moves forward Hiteck's investee Zhongmou Medical won approval to test ZM-02, a gene therapy eye injection for a blinding retinal disease. It adds a second pipeline option, but the company itself warns it will not affect near-term results.

    It shows a second, smaller pipeline advance that supports the long-term story.

  • Core product capacity delayed, losses drag on Investors learned Hiteck's key drug eprinomectin will not add capacity until late 2027, and its CDMO unit keeps losing money. With four straight loss years and a single-product pipeline, near-term profit hopes look distant.

    It explains why the core business cannot quickly offset the losses.

August 2026
▲2▼2

Hiteck's losses widen as chondrosarcoma drug advances

  • Losses keep widening, revenue falling Hiteck's 2026 interim report showed the net loss swelling to 78.71 million yuan, with revenue down 18% and gross margin slipping to 34.25%. A company that keeps losing more money and selling less worries investors, which weighs on the share price.

    The widening loss and falling revenue are the core financial drag on the stock.

  • Chondrosarcoma drug trial approved Regulators approved human trials of Hiteck's injectable epratuzumab for chondrosarcoma, a bone cancer with no approved drug. It is a first-in-class therapy, so success could open a new market, though trials take years and carry high risk.

    This is the main new pipeline catalyst that could lift the stock.

  • Gene therapy investee also moves forward Hiteck's investee Zhongmou Medical won approval to test ZM-02, a gene therapy eye injection for a blinding retinal disease. It adds a second pipeline option, but the company itself warns it will not affect near-term results.

    It shows a second, smaller pipeline advance that supports the long-term story.

  • Core product capacity delayed, losses drag on Investors learned Hiteck's key drug eprinomectin will not add capacity until late 2027, and its CDMO unit keeps losing money. With four straight loss years and a single-product pipeline, near-term profit hopes look distant.

    It explains why the core business cannot quickly offset the losses.

Latest
▲2▼2

Hiteck's losses widen as chondrosarcoma drug advances

  • Losses keep widening, revenue falling Hiteck's 2026 interim report showed the net loss swelling to 78.71 million yuan, with revenue down 18% and gross margin slipping to 34.25%. A company that keeps losing more money and selling less worries investors, which weighs on the share price.

    The widening loss and falling revenue are the core financial drag on the stock.

  • Chondrosarcoma drug trial approved Regulators approved human trials of Hiteck's injectable epratuzumab for chondrosarcoma, a bone cancer with no approved drug. It is a first-in-class therapy, so success could open a new market, though trials take years and carry high risk.

    This is the main new pipeline catalyst that could lift the stock.

  • Gene therapy investee also moves forward Hiteck's investee Zhongmou Medical won approval to test ZM-02, a gene therapy eye injection for a blinding retinal disease. It adds a second pipeline option, but the company itself warns it will not affect near-term results.

    It shows a second, smaller pipeline advance that supports the long-term story.

  • Core product capacity delayed, losses drag on Investors learned Hiteck's key drug eprinomectin will not add capacity until late 2027, and its CDMO unit keeps losing money. With four straight loss years and a single-product pipeline, near-term profit hopes look distant.

    It explains why the core business cannot quickly offset the losses.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.